A 'Polypill' aimed at preventing cardiovascular disease could prove highly cost-effective for use in Latin America

Leonelo E. Bautista, Lina M. Vera-Cala, Daniel Ferrante, Víctor M. Herrera, J. Jaime Miranda, Rafael Pichardo, José R. Sánchez Abanto, Catterina Ferreccio, Eglé Silva, Myriam Oróstegui Arenas, Julio A. Chirinos, Josefina Medina-Lezama, Cynthia M. Pérez, Norberto Schapochnik, Juan P. Casas

Research output: Contribution to journalArticlepeer-review

23 Scopus citations

Abstract

We evaluated the cost-effectiveness of administering a daily "polypill" consisting of three antihypertensive drugs, a statin, and aspirin to prevent cardiovascular disease among high-risk patients in Latin America. We found that the lifetime risk of cardiovascular disease could be reduced by 15 percent in women and by 21 percent in men if the polypill were used by people with a risk of cardiovascular disease equal to or greater than 15 percent over ten years. Attaining this goal would require treating 26 percent of the population at a cost of $34-$36 per quality-adjusted life-year. Offering the polypill to women at high risk and to men age fifty-five or older would be the best approach and would yield acceptable incremental cost-effectiveness ratios. The polypill would be very cost-effective even in the country with the lowest gross national income in our study. However, policy makers must weigh the value of intervention with the polypill against other interventions, as well as their country's willingness and ability to pay for the intervention.

Original languageEnglish
Pages (from-to)155-164
Number of pages10
JournalHealth Affairs
Volume32
Issue number1
DOIs
StatePublished - 2013

Fingerprint

Dive into the research topics of 'A 'Polypill' aimed at preventing cardiovascular disease could prove highly cost-effective for use in Latin America'. Together they form a unique fingerprint.

Cite this